miR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4

详细信息    查看全文

• 作者：Wenhao Ren (1)
  Xiaolong Wang (1)
  Ling Gao (1) (2)
  Shaoming Li (1)
  Xiaojing Yan (1)
  Jin Zhang (1)
  Chen Huang (2)
  Yincheng Zhang (1)
  Keqian Zhi (1) (3)
  
• 关键词：miR ; 21 ; PDCD4 ; Chemosensitivity ; Tongue squamous cell carcinoma cells ; Cisplatin
• 刊名：Molecular and Cellular Biochemistry
• 出版年：2014
• 出版时间：May 2014
• 年：2014
• 卷：390
• 期：1-2
• 页码：253-262
• 全文大小：1,887 KB
• 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-0. doi:10.3322/caac.20107 CrossRef
  2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-9. doi:10.3322/caac.20138 CrossRef
  3. Gibson MK, Forastiere AA (2006) Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol 7:565-74. doi:10.1016/S1470-2045(06)70757-4 CrossRef
  4. O’Neill VJ, Twelves CJ (2002) Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 87:933-37 CrossRef
  5. Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63:12-1. doi:10.1016/j.critrevonc.2007.02.001 CrossRef
  6. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-97. doi:10.1016/s0092-8674(04)00045-5 CrossRef
  7. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522-31. doi:10.1038/nrg1379 CrossRef
  8. Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259-69 CrossRef
  9. Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1-2. doi:10.1016/j.ydbio.2006.08.028 CrossRef
  10. Blower PE, Chung J-H, Verducci JS, Lin S, Park J-K, Dai Z, Liu C-G, Schmittgen TD, Reinhold WC, Croce CM, Weinstein JN, Sadee W (2008) MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7:1-. doi:10.1158/1535-7163.mct-07-0573 CrossRef
  11. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-261. doi:10.1073/pnas.0510565103 CrossRef
  12. Li J, Huang H, Sun L, Yang M, Pan C, Chen W, Wu D, Lin Z, Zeng C, Yao Y, Zhang P, Song E (2009) MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15:3998-008. doi:10.1158/1078-0432.CCR-08-3053 CrossRef
  13. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 107:21098-1103. doi:10.1073/pnas.1015541107 CrossRef
  14. Bai HT, Xu R, Cao ZW, Wei DL, Wang C (2011) Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585:402-08. doi:10.1016/j.febslet.2010.12.027 CrossRef
  15. Gong C, Yao YD, Wang Y, Liu BD, Wu W, Chen JN, Su FX, Yao HR, Song EW (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286:19127-9137. doi:10.1074/jbc.M110.216887 CrossRef
  16. Wang W, Songlin P, Sun Y, Zhang B, Jinhui W (2012) miR-21 inhibitor sensitizes human OSCC cells to cisplatin. Mol Biol Rep 39:5481-485. doi:10.1007/s11033-011-1350-9 CrossRef
  17. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283:1026-033. doi:10.1074/jbc.M707224200 CrossRef
  18. Asangani IA, Rasheed SAK, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H (2007) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27:2128-2136. http://www.nature.com/onc/journal/v27/n15/full/1210856a.html
  19. Jansen AP, Camalier CE, Stark C, Colburn NH (2004) Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 3:103-10
  20. Zhang X, Wang X, Song X, Liu C, Shi Y, Wang Y, Afonja O, Ma C, Chen YH, Zhang L (2010) Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci 101:2163-170. doi:10.1111/j.1349-7006.2010.01664.x CrossRef
  21. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3:1101-108 CrossRef
  22. dos Reis PP, Bharadwaj RR, Machado J, MacMillan C, Pintilie M, Sukhai MA, Perez-Ordonez B, Gullane P, Irish J, Kamel-Reid S (2008) Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer 113:3169-180. doi:10.1002/cncr.23934 CrossRef
  23. Cornelissen M, Philippe J, De Sitter S, De Ridder L (2002) Annexin V expression in apoptotic peripheral blood lymphocytes: an electron microscopic evaluation. Apoptosis 7:41-7 CrossRef
  24. Reis PP, Tomenson M, Cervigne NK, Machado J, Jurisica I, Pintilie M, Sukhai MA, Perez-Ordonez B, Grenman R, Gilbert RW, Gullane PJ, Irish JC, Kamel-Reid S (2010) Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Mol Cancer 9:238. doi:10.1186/1476-4598-9-238 CrossRef
  25. Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M (2010) MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 103:1617-626 CrossRef
  26. Hwang J-H, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim Y-T, Funel N, Park JK, Kim MA, Kang GH, Kim S-W, Chiaro MD, Peters GJ, Giaccone G (2010) Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 5:e10630. doi:10.1371/journal.pone.0010630 CrossRef
  27. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T (2006) Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130:2113-129. doi:10.1053/j.gastro.2006.02.057 CrossRef
  28. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70:4528-538. doi:10.1158/0008-5472.can-09-4467 CrossRef
  29. Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, Zhang CP (2010) MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46:317-22. doi:10.1016/j.oraloncology.2010.02.002 CrossRef
  30. Meng FY, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-58. doi:10.1053/j.gastro.2007.05.022 CrossRef
  31. Zhu S, Si M-L, Wu H, Mo Y-Y (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282:14328-4336. doi:10.1074/jbc.M611393200 CrossRef
  32. Bourguignon LYW, Spevak CC, Wong G, Xia WL, Gilad E (2009) Hyaluronan-CD44 interaction with protein kinase C epsilon promotes oncogenic signaling by the stem cell marker nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284:26533-6546. doi:10.1074/jbc.M109.027466 CrossRef
  33. Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, Ideguchi H, Yamamoto K, Matsuhashi S (2006) Involvement of programmed cell death 4 in transforming growth factor-β1-induced apoptosis in human hepatocellular carcinoma. Oncogene 25:6101-112 CrossRef
  34. Park JK, Lee EJ, Esau C, Schmittgen TD (2009) Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38:E190–E199 CrossRef
  35. Wang P, Zou FD, Zhang XD, Li H, Dulak A, Tomko RJ, Lazo JS, Wang Z, Zhang L, Yu J (2009) MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 69:8157-165. doi:10.1158/0008-5472.can-09-1996 CrossRef
  36. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033-038. http://www.nature.com/nature/journal/v465/n7301/full/nature09144.html
  37. Sumazin P, Yang X, Chiu H-S, Chung W-J, Iyer A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, Califano A (2011) An extensive microRNA-mediated network of RNA–RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147:370-81 CrossRef
  38. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I, Pandolfi PP (2011) Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147:344-57. doi:10.1016/j.cell.2011.09.029 CrossRef
  39. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I (2011) A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147:358-69 CrossRef
  40. Karreth Florian A, Tay Y, Perna D, Ala U, Tan Shen M, Rust Alistair G, DeNicola G, Webster Kaitlyn A, Weiss D, Perez-Mancera Pedro A, Krauthammer M, Halaban R, Provero P, Adams David J, Tuveson David A, Pandolfi Pier P (2011) In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95. doi:10.1016/j.cell.2011.09.032 CrossRef
  
• 作者单位：Wenhao Ren (1)
  Xiaolong Wang (1)
  Ling Gao (1) (2)
  Shaoming Li (1)
  Xiaojing Yan (1)
  Jin Zhang (1)
  Chen Huang (2)
  Yincheng Zhang (1)
  Keqian Zhi (1) (3)
  
  1. Department of Oral and Maxillofacial Surgery/Head and Neck Surgery, Stomatological Hospital, College of Stomatology, Xi’an Jiaotong University, Xi’an, 710004, Shaanxi, China
  2. Department of Genetics and Molecular Biology, College of Medicine, Xi’an Jiaotong University, Xi’an, 710061, Shaanxi, China
  3. Department of Oral and Maxillofacial Surgery, Stomatological Hospital, College of Stomatology, Xi’an Jiaotong University, Number 98, Xiwu Road, Xi’an, 710004, Shaanxi, China
  
• ISSN：1573-4919

文摘

Chemoresistance is a challenge for clinician in management of tongue cancer. Therefore, it is necessary to explore alternative therapeutic methods to overcome drug resistance. miRNAs are endogenous ?2nt RNAs that play important regulatory roles by targeting mRNAs. miR-21, an essential oncogenic molecule, is associated with chemosensitivity of several human cancer cells to anticancer agents. In this study, we investigated the effects and molecular mechanisms of miR-21 in chemosensitivity of tongue squamous cell carcinoma cells (TSCC) to cisplatin. miR-21 expression was detected in tongue cancer tissue using RT-PCR and PDCD4 protein expression was measured using immunohistochemistry. miR-21 and(or) PDCD4 depleted cell lines were generated using miR-21 inhibitor and(or) siRNA. The viabilities of treated cells were analyzed using MTT assay. RT-PCR was used to detect miR-21 expression and immunoblotting was used to detect protein levels. Cell cycle and apoptosis were analyzed using propidium iodide (PI) staining and Annexin V/PI staining, respectively. The expression of miR-21 in tumorous tissue was significantly higher compared with adjacent normal tissue and loss of PDCD4 expression was observed in TSCCs. Transfection of miR-21 inhibitor induced sensitivity of TSCC cells (Tca8113 and CAL-27) to cisplatin. TSCC cells transfected with PDCD4 siRNA became more resistant to cisplatin therapy. We found an increase PDCD4 protein level following the transfection of miR-21 inhibitor using Western blot analysis. In addition, the enhanced growth-inhibitory effect by miR-21 inhibitor was weakened after the addition of PDCD4 siRNA. Suppression of miR-21 or PDCD4 could significantly promote or reduce cisplatin-induced apoptosis, respectively. Our data suggest that miR-21 could modulate chemosensitivity of TSCC cells to cisplatin by targeting PDCD4, and miR-21 may serve as a potential target for TSCC therapy.